We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




AKI Biomarker Described for Pediatric Malaria

By LabMedica International staff writers
Posted on 28 Feb 2018
Acute kidney injury (AKI) is an important complication in severe malaria that is associated with increased mortality in both pediatric and adult populations. More...
However, until recently, the incidence of AKI in pediatric malaria was under-appreciated as few children develop signs of overt renal failure and creatinine testing is not routinely available in resource-constrained settings.

Chitinase-3-like 1 protein (CHI3L1) is a secreted glycoprotein produced by a variety of cell types in response to inflammation, including activated macrophages, neutrophils, and fibroblasts. CHI3L1 is highly expressed in healthy kidney tissue and is freely filtered by the glomerulus. CHI3L1 is also secreted by activated macrophages in the kidney upon stress or damage.

Infectious disease specialists working with their colleagues at the University of Toronto (Toronto, ON, Canada) conducted a study of children in Uganda between 2011 and 2013. Inclusion criteria were age 1–10 years, Plasmodium falciparum by rapid diagnostic test (RDT); using the First Response Malaria Ag. HRP2/pLDH Combo Rapid Diagnostic Test and selected severe malaria criteria.

The team assessed creatinine and blood urea nitrogen (BUN) at the point of care using i-STAT CHEM8+ or Crea cartridges plasma samples were collected daily from children during hospitalization (day 1–4), and at follow up (day 14) and stored at − 80 °C until testing. Cystatin C and CHI3L1 were measured by enzyme-linked immunosorbent assay (ELISA). Markers of intravascular hemolysis, endothelial activation and inflammation were measured by ELISA.

The team found that CHI3L1 levels were elevated in patients with AKI and remained higher over hospitalization and admission and CHI3L1 levels were elevated in children who died. A one unit increase in log10 (CHI3L1) was associated with a 4.1-fold increased risk of in-hospital death and a one unit increase in log10 (CHI3L1) was associated with a 3.21-fold increased risk of death by six months. To explore potential pathophysiologic mechanisms linking elevated CHI3L1 and mortality in severe pediatric malaria, admission levels of CHI3L1 were compared with other host markers of immune and endothelial activation. CHI3L1 was correlated with pathways implicated in the pathobiology of severe malaria including markers of endothelial activation.

The authors concluded that CHI3L1 is a novel biomarker of malaria-associated AKI and an independent risk factor for mortality that is associated with well-established pathways of severe malaria pathogenesis including inflammation, endothelial activation, and hemolysis. The study was published on February 15, 2018, in the Malaria Journal.

Related Links:
University of Toronto


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Tracking blood test trends alongside unexplained weight loss may help identify patients at increased cancer risk and support earlier investigation (Image Credit: 123RF)

Blood Test Patterns Improve Cancer Risk Assessment in Primary Care

Unexplained weight loss is a common but nonspecific presentation in primary care that can precede several types of cancer, making referral decisions difficult. Routine blood tests may produce borderline... Read more

Molecular Diagnostics

view channel
Image: NTM are about 200 environmental bacteria found in soil and water that can cause chronic, tuberculosis-like lung infections but are distinct from the Mycobacterium tuberculosis complex (Image Credit: Adobe Stock)

Rapid CRISPR Test Identifies Nontuberculous Mycobacteria Species from Respiratory Samples

Chronic lung infections caused by nontuberculous mycobacteria (NTM) are increasingly recognized but frequently mistaken for tuberculosis, complicating diagnosis and care. These infections may affect as... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Pathology

view channel
Image Credit: Adobe Stock

Machine Learning Cytology Tool Improves Cancer Cell Identification

Cytological screening remains central to early cancer detection, but its accuracy depends heavily on expert interpretation of stained cells. Under conventional microscopy, malignant and reactive cells... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.